<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312474704</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312474704</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Impaired phagocytosis and susceptibility to infection in pediatric-onset systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>S-A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474704">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yeh</surname><given-names>K-W</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474704">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lee</surname><given-names>W-I</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474704">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yao</surname><given-names>T-C</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474704">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kuo</surname><given-names>M-L</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312474704">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname><given-names>B</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312474704">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Huang</surname><given-names>J-L</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474704">1</xref><xref ref-type="aff" rid="aff4-0961203312474704">4</xref>
<xref ref-type="corresp" rid="corresp1-0961203312474704"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203312474704"><label>1</label>Division of Allergy Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan</aff>
<aff id="aff2-0961203312474704"><label>2</label>Department of Microbiology and Immunology, Graduate Institute of Basic Medical Sciences, Chang Gung University, Taoyuan, Taiwan</aff>
<aff id="aff3-0961203312474704"><label>3</label>Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan</aff>
<aff id="aff4-0961203312474704"><label>4</label>College of Medicine, Chang Gung University, Taoyuan,Taiwan</aff>
<author-notes>
<corresp id="corresp1-0961203312474704">Huang Jing-Long, Division of Allergy, Asthma and Rheumatology Department of Pediatrics Chang Gung Memorial Hospital 5, Fu-Hsin Street, Taoyuan, Taiwan. Email: <email>long@adm.cgmh.org.tw</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>3</issue>
<fpage>279</fpage>
<lpage>288</lpage>
<history>
<date date-type="received"><day>19</day><month>6</month><year>2012</year></date>
<date date-type="accepted"><day>18</day><month>12</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013. Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec15-0961203312474704"><title>Objectives</title>
<p>Impaired function of polymorphonuclear cells (PMNs) in systemic lupus erythematosus (SLE) leads to severe gram-positive and gram-negative bacterial infection, and to major morbidity and mortality. Few studies have focused on the association of impaired function of PMNs and SLE patients’ susceptibility to infection. This study aimed to analyze function of PMNs in peroxidase production, chemotaxis, and phagocytosis in pediatric-onset SLE with severe infection.</p>
</sec>
<sec id="sec16-0961203312474704"><title>Methods</title>
<p>This study compared function of PMNs among pediatric-onset SLE patients with and without histories of severe infection and in normal control subjects. Human peripheral blood PMNs were isolated from patients and controls. Function of PMNs was measured by analyzing peroxidase, chemotaxis, and phagocytic activities. Different disease activity and severity, and drug use in newly diagnosed SLE patients were also compared.</p>
</sec>
<sec id="sec17-0961203312474704"><title>Results</title>
<p>In total, 34 SLE patients (12 patients with severe infection, 22 patients without infection) and 25 healthy controls were analyzed. There were no differences in function of PMNs between SLE patients with or without severe infection. Regardless of infection status, medication, and disease activity, SLE patients had impaired phagocytic ability against <italic>Salmonella</italic>-specific lipopolysaccharides (LPS) compared with normal controls (<italic>p </italic>&lt; 0.01). The use of immunosuppressants did not influence phagocytic ability against <italic>Salmonella</italic>-derived LPS.</p>
</sec>
<sec id="sec18-0961203312474704"><title>Conclusions</title>
<p>Immunosuppressant agents do not influence phagocytic ability against <italic>Salmonella</italic> in SLE subjects. Impaired phagocytosis against <italic>Salmonella</italic> is prominent in pediatric-onset SLE subjects, which may result in the high prevalence of <italic>Salmonella</italic> infection. There is no deficiency of peroxidase production and chemotaxis activity among SLE subjects.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Systemic lupus erythematosus</kwd>
<kwd><italic>Salmonella</italic> infection</kwd>
<kwd>children</kwd>
<kwd>innate immunity</kwd>
<kwd>polymorphonuclear cells</kwd>
<kwd>phagocytosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312474704" sec-type="intro"><title>Introduction</title>
<p>Innate immunity is the first-line host defense against pathogenic microbes. Its major cellular components are phagocytes such as macrophages, polymorphonuclear cells (PMNs), and dendritic cells (DCs). Dysfunction of PMNs has long been discussed in patients with systemic lupus erythematosus (SLE), and defective phagocytosis of apoptotic cells results in occurrence of SLE.<sup><xref ref-type="bibr" rid="bibr1-0961203312474704">1</xref></sup> In an animal model, a kinetic defect in phagocytic ability was found in SLE subjects.<sup><xref ref-type="bibr" rid="bibr2-0961203312474704">2</xref></sup> While SLE is a multi-factorial systemic disease characterized by an antigen-driven autoimmune response, it is not clear whether the defect found in patients with SLE is intrinsic to their macrophages or is caused by the disease activity itself.<sup><xref ref-type="bibr" rid="bibr3-0961203312474704">3</xref></sup></p>
<p>Patients with SLE are more susceptible to gram-positive and gram-negative bacterial infection<sup><xref ref-type="bibr" rid="bibr4-0961203312474704">4</xref></sup> because they are immunocompromised, and are typically given immunosuppressive drugs to control disease activity. Previous reports have shown that SLE patients with bacterial infection make up the major source of SLE morbidity and mortality worldwide. A multi-center study of SLE outcomes showed that 33% of patients died from infection, and the most common infections among SLE patients are those involving respiratory and urinary tracts.<sup><xref ref-type="bibr" rid="bibr5-0961203312474704">5</xref></sup> One Chinese population-based study indicated that SLE patients were more susceptible to non-typhoid <italic>Salmonella</italic>-related osteomyelitis and septic arthritis, especially during the active disease stage.<sup><xref ref-type="bibr" rid="bibr6-0961203312474704">6</xref>,<xref ref-type="bibr" rid="bibr7-0961203312474704">7</xref></sup> Furthermore, <italic>Salmonella</italic> infection is not only the most common gram-negative bacteria infection among the Chinese population, but is also the most common of opportunistic bacterial infections seen in fatal SLE.<sup><xref ref-type="bibr" rid="bibr8-0961203312474704">8</xref><xref ref-type="bibr" rid="bibr9-0961203312474704"/>–<xref ref-type="bibr" rid="bibr10-0961203312474704">10</xref></sup> Impaired function of PMNs may lead to serial bacterial infection that includes gram-positive and gram-negative microbials.<sup><xref ref-type="bibr" rid="bibr11-0961203312474704">11</xref></sup> The present study aimed to determine the function of PMNs among pediatric-onset SLE patients, and the association with microbial infection.</p>
</sec>
<sec id="sec2-0961203312474704" sec-type="materials|methods"><title>Materials and methods</title>
<p>From December 2002 to December 2009, 34 patients with pediatric-onset SLE on regular follow-up at Chang Gung Memorial Hospital, a tertiary care center in Taiwan, were randomized and enrolled in this cross-sectional study. All patients were diagnosed with SLE when they were aged younger than 18 years, and all fulfilled the diagnostic criteria for SLE proposed by the American College of Rheumatology 1982.<sup><xref ref-type="bibr" rid="bibr12-0961203312474704">12</xref></sup> An informed consent was obtained from both the children and their parents before enrollment, and the hospital ethics committee (IRB number: 97-2290B) approved the study. All of the patients were assessed in terms of clinical manifestations, disease activity indices, and treatment regimens. Patients with disseminated bacteremia resulting from blood stream or urine infection were defined as having major infection and requiring intravenous antibiotics treatment. They were classified as having inactive disease if their SLE disease activity index score (SLEDAI) was consistently below 4 points for at least 3 months.<sup><xref ref-type="bibr" rid="bibr13-0961203312474704">13</xref></sup> Immunosuppressants such as azathioprine, cyclophosphamide, and steroids, as well as steroid cumulative dosage, were recorded. Newly diagnosed patients had their PMN function tested immediately after diagnosis of SLE and prior to any immunosuppressant medication.</p>
<p>In total, 34 SLE patients and 25 normal control (NC) subjects completed the analysis of PMN function. Of the 34 SLE patients, 10 were newly diagnosed, 25 were in the active disease stage and nine in the inactive stage; twelve of 34 patients had major infection, including nine with history of infection, three with current infection, and 22 without history of major infection. The characteristics of the 12 SLE patients with major infection are summarized in <xref ref-type="table" rid="table1-0961203312474704">Table 1</xref>. We included 25 senior high school students as control subjects (19 were female and six were male); their mean age was 15.68 ± 1.17 (years), and the median age was 16 years old (<xref ref-type="table" rid="table2-0961203312474704">Table 2</xref>). The control subjects had not had any chronic disease or medication in the previous year. The SLEDAI score was only used to assess the SLE patients. Cumulative doses of steroids before enrollment were recorded.
<table-wrap id="table1-0961203312474704" position="float"><label>Table 1</label><caption><p>Characteristics of pediatric-onset SLE with infection</p></caption>
<graphic alternate-form-of="table1-0961203312474704" xlink:href="10.1177_0961203312474704-table1.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th/><th>Time to blood sample (days)</th><th>Bacterial</th><th>Immunosuppressant agents</th><th>SLE stage (SLEDAI)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>PT1</td>
<td>96</td>
<td>Sepsis: <italic>Group D Salmonella</italic></td>
<td>yes</td>
<td>active (11)</td>
</tr>
<tr>
<td>PT2</td>
<td>1600</td>
<td>Sepsis: <italic>S. pyogenes</italic></td>
<td>yes</td>
<td>active (4)</td>
</tr>
<tr>
<td>PT3</td>
<td>0</td>
<td>Urosepsis: <italic>Escherichia coli</italic></td>
<td>no</td>
<td>active (12)</td>
</tr>
<tr>
<td>PT4</td>
<td>2472</td>
<td>Sepsis: <italic>Group B Salmonella</italic></td>
<td>yes</td>
<td>active (4)</td>
</tr>
<tr>
<td>PT5</td>
<td>214</td>
<td>Sepsis: <italic>Staphylococcus aureus</italic></td>
<td>yes</td>
<td>active (4)</td>
</tr>
<tr>
<td>PT6</td>
<td>2555</td>
<td>Sepsis: <italic>S. pneumoniae</italic></td>
<td>yes</td>
<td>active (6)</td>
</tr>
<tr>
<td>PT7</td>
<td>1767</td>
<td>Urosepsis: <italic>S. pyogenes</italic></td>
<td>yes</td>
<td>inactive (2)</td>
</tr>
<tr>
<td>PT8</td>
<td>122</td>
<td>Sepsis: <italic>Enterobacter cloace</italic></td>
<td>yes</td>
<td>active (6)</td>
</tr>
<tr>
<td>PT9</td>
<td>210</td>
<td>Sepsis: <italic>S. pyogenes</italic></td>
<td>yes</td>
<td>inactive (2)</td>
</tr>
<tr>
<td>PT10</td>
<td>0</td>
<td>Sepsis: <italic>S. pneumoniae</italic></td>
<td>no</td>
<td>active (14)</td>
</tr>
<tr>
<td>PT11</td>
<td>14</td>
<td>Sepsis: <italic>S. pneumoniae</italic></td>
<td>yes</td>
<td>active (9)</td>
</tr>
<tr>
<td>PT12</td>
<td>92</td>
<td>Urosepsis: <italic>Cryptococcus neoformans</italic></td>
<td>yes</td>
<td>inactive (2)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0961203312474704"><p>Characteristics of infection including seven patients with streptococcal species infection and two patients with <italic>Salmonella</italic> infection. NC: normal control; SLE: systemic lupus erythematosus; SLEDAI&gt; 4 points, active SLE.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0961203312474704" position="float"><label>Table 2</label><caption><p>Clinical characteristics of children with systemic lupus erythematosus (SLE) (<italic>n </italic>= 34)<xref ref-type="table-fn" rid="table-fn7-0961203312474704">*</xref></p></caption>
<graphic alternate-form-of="table2-0961203312474704" xlink:href="10.1177_0961203312474704-table2.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th/><th>Patients (<italic>n </italic>= 34)<hr/></th>
</tr>
<tr><th><bold>Characteristics</bold></th><th><bold>Mean</bold> ± <bold>SD</bold></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age at diagnosis (years)</td>
<td>13.15 ± 3.43</td>
</tr>
<tr>
<td>Range (years)</td>
<td>8.84∼16.14</td>
</tr>
<tr>
<td>Gender (Male/Female)</td>
<td>6/28</td>
</tr>
<tr>
<td>Follow-up duration (years)</td>
<td>3.92 ± 3.33</td>
</tr>
<tr>
<td>Nephritis (Number/%)</td>
<td>17 (50.0)</td>
</tr>
<tr>
<td>CNS lupus (Number/%)</td>
<td>4 (11.8)</td>
</tr>
<tr>
<td>Active SLE (Number/%)</td>
<td>25 (73.5)</td>
</tr>
<tr>
<td>Range of active SLE (SLEDAI)</td>
<td>4∼19</td>
</tr>
<tr>
<td>Mean/median of active SLE (SLEDAI)</td>
<td>8.96 ± 3.53/9</td>
</tr>
<tr>
<td>Mean/median of inactive SLE (SLEDAI)</td>
<td>1.54 ± 0.63/2</td>
</tr>
<tr>
<td>SLE with severe infection (Number/%)</td>
<td>12 (35.3)</td>
</tr>
<tr>
<td>Newly diagnosed SLE</td>
<td>10 (29.4)</td>
</tr>
<tr>
<td colspan="2"><bold>Immunosuppressant use (number/%)</bold></td>
</tr>
<tr>
<td>Methylprednisolone pulse therapy</td>
<td>11 (32.3)</td>
</tr>
<tr>
<td>Cyclophosphamide pulse therapy</td>
<td>15 (44.1)</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>12 (35.3)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0961203312474704"><label>*</label><p>Including age, follow-up duration, major organ involvement, and use of immunosuppressants.</p></fn></table-wrap-foot>
</table-wrap>
</p>
<sec id="sec3-0961203312474704"><title>Preparation of mononuclear cells</title>
<p>Peripheral blood mononuclear cells (PBMCs) were isolated by dextran (4.5%), and red blood cell (RBC) sedimentation at a ratio of 1:5 separated leukocytes from RBCs. Leukocytes were separated into mononuclear cells (MNCs) and PMNs by density gradient centrifugation (Ficoll-Paque; Amersham Pharmacia, Biotech AB, Uppsala, Sweden). PMNs were counted and suspended to 2 × 10<sup>6</sup>/ml in RPMI-1640. Freshly isolated PMNs (2 × 10<sup>6</sup>/ml) were obtained from SLE patients and healthy controls.<sup><xref ref-type="bibr" rid="bibr14-0961203312474704">14</xref></sup></p>
</sec>
<sec id="sec4-0961203312474704"><title>Assessment of function of PMNs and flow cytometric analysis</title>
<p>Using normal healthy subjects as standard values (100%), H<sub>2</sub>O<sub>2</sub> (peroxidase) production activity was compared among three sub-groups of SLE patients. PMNs were stimulated with PMA reagents to produce peroxidase and DCFH was used to react with PMNs. Fluorescence microscopy was used to measure peroxidase production.</p>
<p>After absorption by FMLP (formyl-methiony-leucylanalin), chemotaxis function was compared among three sub-groups of SLE patients. Preparations were scored by two independent observers at 400 × magnification using light microscopy to evaluate chemotaxis.</p>
<p>Commercial BioParticles products from Molecular Probes, Inc. were employed to study phagocytosis by fluorescence microscopy, quantitative spectrofluorometry, and flow cytometry. <italic>Escherichia coli</italic> (K-12 strain) and <italic>Staphylococcus aureus</italic> (Wood strain, without protein A) conjugates were covalently labeled with a variety of different fluorophores. <italic>E. coli</italic> was labeled with E-2864 and <italic>S. aureus</italic> was labeled with S-2854. Using BioParticles conjugates, the fluorescence of the BODIPY FL conjugates was uniformly intense over a broad pH range (pH 4.9). Phagocytic activity was measured using flow cytometric analysis by calculating the area of activated PMNs by quantitative spectrofluorometry.<sup><xref ref-type="bibr" rid="bibr15-0961203312474704">15</xref><xref ref-type="bibr" rid="bibr16-0961203312474704"/><xref ref-type="bibr" rid="bibr17-0961203312474704"/>–<xref ref-type="bibr" rid="bibr18-0961203312474704">18</xref></sup> Lipopolysaccharides (LPS) or endotoxins are complex macromolecules on the outer cell walls of gram-negative bacteria. Using BODIPY FL-derived LPS from <italic>Salmonella minnesota</italic>, phagocytic activity toward <italic>Salmonella</italic> infection was measured under quantitative spectrofluorometry.<sup><xref ref-type="bibr" rid="bibr19-0961203312474704">19</xref></sup></p>
</sec>
<sec id="sec5-0961203312474704"><title>Statistical analysis</title>
<p>Comparisons of function of PMNs, including peroxidase production, chemotaxis, and phagocytosis were made among the three SLE sub-groups and in the control group according to different criteria. For all major results, 95% confidence intervals (CIs) are given. All comparisons between SLE patients and the NCs were made by one-way analysis of variance (ANOVA). A two-tailed <italic>p </italic>≤ 0.01 was considered statistically significant. The cumulative steroid dose was adjusted by linear regression analysis and a <italic>p </italic>&lt; 0.05 was viewed as significant.</p>
</sec>
</sec>
<sec id="sec6-0961203312474704" sec-type="results"><title>Results</title>
<p>The mean age at SLE diagnosis of the 34 enrolled SLE patients was 13.15 ± 2.43 years (range, 8.84–16.14 years) and mean follow-up duration was 3.92 ± 3.33 years. The cumulative frequency of lupus nephropathy was 50.0%, and class IV nephritis was the most common histopathologic finding. The cumulative frequency of neuro-psychiatric abnormalities was 11.8%. Eleven (32.3%) patients received intravenous methylprednisolone pulse therapy, while 15 (44.1%) received intravenous cyclophosphamide pulse therapy.</p>
<sec id="sec7-0961203312474704"><title>Function of PMNs in SLE patients with and without severe infection</title>
<p>Peroxidase (H<sub>2</sub>O<sub>2</sub>) production and chemotaxis activity among SLE subjects and NC subjects were not significantly different and did not influence disease activity (both <italic>p </italic>&gt; 0.01). Phagocytic ability against <italic>S. aureus</italic> in SLE patients with and without major infection was 87.12 ± 7.39% and 88.28 ± 3.90%, respectively, and 91.52 ± 5.06% in the controls. Phagocytosis against <italic>E. coli</italic> in SLE patients with and without severe infection and in NC was 87.93 ± 6.63, 87.92 ± 7.17, and 88.25 ± 5.03%, respectively. There was no significant difference in phagocytic activity against <italic>S. aureus</italic> and <italic>E. coli</italic> among the three groups.</p>
<p>After stimulating with <italic>Salmonella</italic>-derived LPS, phagocytic ability in SLE patients with and without major infection and in NC was 76.87 ± 21.17%, 73.28 ± 21.07, and 94.32 ± 2.88% (<italic>p </italic>≤ 0.01). There was no difference in phagocytic ability in patients with SLE, regardless of severe infection. Phagocytic activity against <italic>Salmonella</italic>-specific LPS in both SLE patients with and without severe infection was lower compared with NC (<xref ref-type="table" rid="table3-0961203312474704">Table 3</xref> and <xref ref-type="table" rid="table4-0961203312474704">Appendix 1</xref>).
<table-wrap id="table3-0961203312474704" position="float"><label>Table 3</label><caption><p>Phagocytic activity among normal control (NC) and SLE patients</p></caption><graphic alternate-form-of="table3-0961203312474704" xlink:href="10.1177_0961203312474704-table3.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th/><th>Normal control</th><th>SLE without history of infection</th><th>SLE with history of infection</th><th>Inactive SLE</th><th>Active SLE</th><th>SLE without immuno suppressant medication</th><th>SLE with immunosuppressant medication</th><th>SLE</th>
</tr>
<tr>
<td>Number</td><th><italic>n </italic>= 25</th><th><italic>n </italic>= 22</th><th><italic>n </italic>= 12</th><th><italic>n </italic>= 9</th><th><italic>n </italic>= 25</th><th><italic>n </italic>= 10</th><th>N<italic> </italic>= 24</th><th>N<italic> </italic>= 34</th>
</tr></thead>
<tbody align="left">
<tr>
<td>H<sub>2</sub>O<sub>2</sub> production Mean ± SD (%)</td>
<td>98.71 ± 0.33</td>
<td>98.81 ± 0.45</td>
<td>98.71 ± 0.39</td>
<td>97.86 ± 2.50</td>
<td>99.13 ± 0.92</td>
<td>99.57 ± 0.25</td>
<td>98.68 ± 1.75</td>
<td>98.78 ± 1.58</td>
</tr>
<tr>
<td>Chemotaxis ability Mean ± SD (%)</td>
<td>63.2 ± 12.90</td>
<td>52.1 ± 23.56</td>
<td>58.92 ± 32.57</td>
<td>60.22 ± 12.14</td>
<td>52.28 ± 29.98</td>
<td>56.40 ± 44.26</td>
<td>53.78 ± 15.72</td>
<td>54.55 ± 21.72</td>
</tr>
<tr>
<td>Phagocytosis against <italic>E. coli</italic> Mean ± SD (%)</td>
<td>88.25 ± 5.03</td>
<td>87.92 ± 7.17</td>
<td>87.93 ± 6.63</td>
<td>84.93 ± 7.78</td>
<td>88.88 ± 6.43</td>
<td>90.74 ± 8.72</td>
<td>86.70 ± 5.70</td>
<td>87.56 ± 6.80</td>
</tr>
<tr>
<td>Phagocytosis against <italic>S. aureus</italic> Mean ± SD (%)</td>
<td>91.52 ± 5.06</td>
<td>87.12 ± 7.39</td>
<td>88.28 ± 3.90</td>
<td>86.44 ± 4.84</td>
<td>87.9 ± 6.75</td>
<td>87.92 ± 9.65</td>
<td>87.38 ± 4.41</td>
<td>87.56 ± 6.41</td>
</tr>
<tr>
<td>Phagocytosis against LPS (<italic>Salmonella</italic>) Mean ± SD (%)</td>
<td>94.32 ± 2.88</td>
<td>73.28 ± 21.07<xref ref-type="table-fn" rid="table-fn6-0961203312474704">*</xref></td>
<td>76.87 ± 21.17<xref ref-type="table-fn" rid="table-fn6-0961203312474704">*</xref></td>
<td>73.57 ± 22.66<xref ref-type="table-fn" rid="table-fn6-0961203312474704">*</xref></td>
<td>74.91 ± 20.71<xref ref-type="table-fn" rid="table-fn6-0961203312474704">*</xref></td>
<td>71.55 ± 18.90<xref ref-type="table-fn" rid="table-fn6-0961203312474704">*</xref></td>
<td>75.91 ± 21.90<xref ref-type="table-fn" rid="table-fn6-0961203312474704">*</xref></td>
<td>74.91 ± 19.67<xref ref-type="table-fn" rid="table-fn6-0961203312474704">*</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0961203312474704"><p>Phagocytosis against LPS (<italic>Salmonella</italic>) antigen was lower in SLE patients despite history of infection, disease status, or immunosuppressant agent usage compared with NC (all <italic>p </italic>≤ 0.01). NC: normal control; SLE: systemic lupus erythematosus; SD: standard deviation.</p></fn>
<fn id="table-fn6-0961203312474704"><label>*</label><p><italic>p </italic>≤ 0.01</p></fn></table-wrap-foot>
</table-wrap>
</p>
</sec>
<sec id="sec8-0961203312474704"><title>Function of PMNs in active and inactive SLE</title>
<p>Chemotaxis among SLE and NC subjects was not influenced by disease activity or peroxidase production (<xref ref-type="table" rid="table3-0961203312474704">Table 3</xref> and <xref ref-type="table" rid="table5-0961203312474704">Appendix 2</xref>). Disease activity did not influence either chemotaxis or peroxidase activity. Phagocytosis against <italic>S. aureus</italic> and <italic>E. coli</italic> in patients with active and inactive SLE and in NCs was not significantly different. Phagocytic ability after stimulation with LPS was 74.91 ± 20.71, 73.57 ± 22.66, and 94.32 ± 2.88%, respectively. Thus, phagocytosis against <italic>Salmonella</italic>-specific LPS was much lower in SLE patients regardless of disease active and inactive stage, compared with the NC (<italic>p </italic>≤ 0.01).</p>
</sec>
<sec id="sec9-0961203312474704"><title>Function of PMNs in SLE patients with and without immunosuppressant medication</title>
<p>Similarly, there was no significant difference in chemotaxis and peroxidase production activity in SLE patients with and without immunosuppressant medication, and in the controls. Regardless of use of immunosuppressant, phagocytosis against <italic>S. aureus</italic> and <italic>E. coli</italic> was not different among the three groups, but phagocytic activity stimulated by <italic>Salmonella</italic>-specific LPS was 71.55 ± 18.90, 75.91 ± 21.90, and 94.32 ± 2.88%, respectively. Phagocytosis against <italic>Salmonella</italic>-specific LPS was lower in SLE patients regardless of immunosuppressant use compared with the NC (<italic>p </italic>≤ 0.01) (<xref ref-type="table" rid="table3-0961203312474704">Table 3</xref> and <xref ref-type="table" rid="table6-0961203312474704">Appendix 3</xref>).</p>
<p>Phagocytosis against <italic>Salmonella</italic> infection in SLE subjects was significantly lower regardless of immunosuppressant use, presence of infection and worse disease severity. There was no significant correlation between cumulative steroid dose and phagocytic ability against <italic>Salmonella</italic> infection by linear regression analysis (<italic>p </italic>= 0.30). Regarding the influence of immunosuppressant agents on phagocytic ability against <italic>Salmonella</italic> infection, there was no obvious difference among steroids, cyclophosphamide, and azathioprine (<xref ref-type="fig" rid="fig1-0961203312474704">Figure 1(a)</xref> and (<xref ref-type="fig" rid="fig1-0961203312474704">b</xref>)).
<fig id="fig1-0961203312474704" position="float"><label>Figure 1</label><caption><p>(a) There was no significant correlation between cumulative steroid dose and phagocytosis ability against <italic>Salmonella</italic>-specific LPS (<italic>p </italic>= 0.30; by linear regression analysis). (b) There was no significantly different influence on phagocytosis ability against <italic>Salmonella</italic>-specific LPS in patients using steroids, cyclophosphamide, and azathioprine. MP: methylprednisolone pulse therapy; CYC: cyclophosphamide pulse therapy; AZA: azathioprine.</p></caption><graphic xlink:href="10.1177_0961203312474704-fig1.tif"/>
</fig></p>
</sec>
</sec>
<sec id="sec10-0961203312474704" sec-type="discussion"><title>Discussion</title>
<p>Dysfunction of PMNs has long been discussed in SLE patients; in particular, defective phagocytosis towards apoptotic cells leading to auto-antibody accumulation has been regarded as one possible mechanism contributing to SLE.<sup><xref ref-type="bibr" rid="bibr1-0961203312474704">1</xref></sup> Deficient functioning of PMNs results in high susceptibility to a series of bacterial infections, including <italic>S. aureus, E. coli</italic>, and <italic>Salmonella</italic>.<sup><xref ref-type="bibr" rid="bibr20-0961203312474704">20</xref></sup> To date, whether or not the high incidence of dysfunction of PMNs in patients with SLE contributes to bacterial infection remains unclear. The present study attempts to analyze the connection of the functioning of PMNs and major infection in pediatric-onset SLE subjects. Comparison was made among SLE patients with and without severe bacterial infection, and with normal healthy subjects to identify any major difference between SLE subjects and normal healthy subjects. The results of this study indicate that SLE patients have obvious impairment of phagocytosis towards <italic>Salmonella</italic> regardless of disease severity, immunosuppressants, and infection status (all <italic>p </italic>&lt; 0.01). Nonetheless, immunosuppressant use means that SLE patients are more susceptible to infections, but does not influence phagocytosis towards <italic>Salmonella</italic> (<italic>p </italic>= 0.30). There is no significant difference in the function of PMNs among the SLE patients.</p>
<p>Impaired function of PMNs in SLE patients has been observed in several studies, and several mechanisms have been discussed, including decrease in spontaneous and in LPS-stimulated production of interleukin-8 by neutrophils, serum factor dysregulation, decreased TNF-α production, and the presence of FcRII antibody. Moreover, a defective PMNs response in SLE patients is considered contributory to impaired cell-mediated immunity rather than humoral immunity. Janko et al. indicated that phagocytes from patients with lupus engulfed far less apoptotic material than phagocytes from healthy people during a 7-day culture period.<sup><xref ref-type="bibr" rid="bibr21-0961203312474704">21</xref><xref ref-type="bibr" rid="bibr22-0961203312474704"/>–<xref ref-type="bibr" rid="bibr23-0961203312474704">23</xref></sup> As well as the intrinsic defect of phagocytic function among SLE patients, phagocytic activity is reportedly further suppressed during the SLE active stage. Ren et al. found this impaired phagocytic ability through a macrophage study in patients with active SLE stage compared with a healthy control. In addition, Passero et al. found that the number of macrophage cells in inflammatory pleural effusion was decreased, with defective reaction to skin test antigens, in patients with SLE.<sup><xref ref-type="bibr" rid="bibr24-0961203312474704">24</xref><xref ref-type="bibr" rid="bibr25-0961203312474704"/><xref ref-type="bibr" rid="bibr26-0961203312474704"/><xref ref-type="bibr" rid="bibr27-0961203312474704"/>–<xref ref-type="bibr" rid="bibr28-0961203312474704">28</xref></sup> Among chemotaxis, peroxidase production, and phagocytosis against microbial infection, deficiencies in the recognition and phagocytosis of dying cells have been shown as one of the main alterations in SLE patients.<sup><xref ref-type="bibr" rid="bibr23-0961203312474704">23</xref></sup> Whether or not altered recognition in PMNs leads to high bacterial susceptibility among patients wit SLE warrants further investigation.</p>
<p>The impairment of peroxidase production causes the patients to be more susceptible to recurrent and unusual infections, with <italic>S. aureus</italic> as the most common microbial pathogen. After bacterial infection, chemotaxis forces PMNs to migrate to the site of infection via release of molecules from the microbes. A deficiency in chemotaxis makes patients more easily susceptible to pyogenic infection. Defects in phagocytosis make people susceptible to <italic>S. aureus</italic> and enteric gram-negative infections such as <italic>E. coli</italic> and <italic>Salmonella.</italic> Consequently, deficient functioning of PMNs leads to recurrent infection, whether with gram-positive or gram-negative pathogens.<sup><xref ref-type="bibr" rid="bibr20-0961203312474704">20</xref></sup></p>
<p>Although SLE is an autoimmune disease that typically involves multiple organs, infection is a predominant cause of mortality. Previous studies indicate that SLE patients with infections have poorer outcomes, and nearly 40% of SLE patients have at least one episode of infection even if they do not take immunosuppressants. Alterations in both innate and adaptive immune responses may be associated with increased risk for infection.<sup><xref ref-type="bibr" rid="bibr29-0961203312474704">29</xref>,<xref ref-type="bibr" rid="bibr30-0961203312474704">30</xref></sup> Bacterial infections are responsible for most infections in SLE, and the most commonly identified are <italic>S. aureus, Streptococcus pyogenes</italic>, <italic>Streptococcus pneumoniae</italic>, and <italic>E. coli</italic>.<sup><xref ref-type="bibr" rid="bibr31-0961203312474704">31</xref></sup> One large cohort study on SLE subjects in a Chinese population showed bacteremia with unfavorable long-term outcomes. Furthermore, rather than infection with streptococcus species, the Chinese population was more susceptible to non-typhoid <italic>Salmonella</italic> infection in all types of infections.<sup><xref ref-type="bibr" rid="bibr5-0961203312474704">5</xref><xref ref-type="bibr" rid="bibr6-0961203312474704"/><xref ref-type="bibr" rid="bibr7-0961203312474704"/><xref ref-type="bibr" rid="bibr8-0961203312474704"/><xref ref-type="bibr" rid="bibr9-0961203312474704"/>–<xref ref-type="bibr" rid="bibr10-0961203312474704">10</xref></sup></p>
<p>It has been reported that 16–47% of SLE patients will suffer from bacteremia during their life. Among the bacteremia cases, 20% are non-typhoid salmonellosis. The life-long incident rate of salmonellosis is as high as 40% in one series, compared with 2% in the general population. Some SLE subjects have concurrent salmonellosis on the first presentation of lupus. In a large hospital-based cohort study, SLE was the most frequent underlying chronic disease with gram-negative bacteremia, and the most common bacteria was <italic>Salmonella</italic>. It may be an uncommon pathogen for osteomyelitis and septic arthritis in the general population, but it is the most common bacterial infection in SLE patients.<sup><xref ref-type="bibr" rid="bibr32-0961203312474704">32</xref><xref ref-type="bibr" rid="bibr33-0961203312474704"/><xref ref-type="bibr" rid="bibr34-0961203312474704"/>–<xref ref-type="bibr" rid="bibr35-0961203312474704">35</xref></sup> Several clinical risk factors of salmonellosis have been described, including lupus nephritis, older age, functional hypo-splenism, avascular necrosis of the femoral head, and other concomitant infections.<sup><xref ref-type="bibr" rid="bibr9-0961203312474704">9</xref>,<xref ref-type="bibr" rid="bibr10-0961203312474704">10</xref>,<xref ref-type="bibr" rid="bibr32-0961203312474704">32</xref></sup> However, it remains unclear if the high susceptibility to <italic>Salmonella</italic> is due to impaired functioning of PMNs. The current study shows that, compared with healthy controls, SLE patients have impaired PMN phagocytic activity against <italic>Salmonella</italic>, which may be responsible for increased susceptibility to infection with this organism. As a consequence, defects in phagocytosis against <italic>Salmonella</italic>-related LPS may contribute to the high prevalence rate of non-typhoid <italic>Salmonella</italic> infection among SLE patients. Few studies have focused on chemotaxis and peroxidase production ability. Comparing the three sub-groups of SLE patients and the NC subjects in this study, there are no significant differences in chemotaxis and peroxidase activity.</p>
<p>Previous studies indicate that corticosteroids and immunosuppressive drugs such as cyclophosphamide, azathioprine, and methotrexate are independent risk factors for infection.<sup><xref ref-type="bibr" rid="bibr36-0961203312474704">36</xref></sup> Studies on adult-onset SLE reveals that steroid use increases the risk of infection in a dose-dependent manner.<sup><xref ref-type="bibr" rid="bibr37-0961203312474704">37</xref></sup> Illei et al. reported that a combination regimen of methylprednisolone and cyclophosphamide pulse therapy is associated with higher frequency of infection than a single-agent regimen in adult-onset SLE.<sup><xref ref-type="bibr" rid="bibr38-0961203312474704">38</xref>,<xref ref-type="bibr" rid="bibr39-0961203312474704">39</xref></sup> Although the immunosuppressant effect is not as strong as that of cyclophosphamide and steroids, a single regimen of azathioprine also reportedly increases the risk of infection in SLE patients.<sup><xref ref-type="bibr" rid="bibr40-0961203312474704">40</xref></sup> In contrast, by studying PMN phagocytosis towards apoptotic cells in SLE patients, Ren et al. indicated that immunosuppressant agents do not influence phagocytic ability even if patients are under high doses of corticosteroids.<sup><xref ref-type="bibr" rid="bibr24-0961203312474704">24</xref></sup> In our study, 10 newly diagnosed SLE subjects were enrolled to minimize the possibility of cumulative drug effects. Comparisons made between SLE patients with and without immunosuppressant agents showed no difference in phagocytosis against <italic>Salmonella</italic> infection. Further estimating the cumulative steroid dose also indicated no significant dose effect of steroids on phagocytic ability. Analysis made among steroids, cyclophosphamide, and azathioprine indicated that no single agent plays a major role in interfering with phagocytosis.</p>
<p>While a previous study showed that the disease activity stage could influence phagocytosis,<sup><xref ref-type="bibr" rid="bibr24-0961203312474704">24</xref></sup> the present study failed to find any significant difference between patients with active and inactive SLE. The same results were observed between patients with and without severe infection as regards <italic>E. coli</italic>, <italic>S. aureus</italic>, and <italic>Salmonella</italic>. In spite of the species of bacterial infection, the tendency of deficiency in phagocytosis against <italic>Salmonella</italic> infection was obvious.</p>
<p>This study has several limitations. First, there was no sequential follow-up on phagocytic ability in SLE patients. Instead, 10 newly diagnosed SLE subjects were enrolled before initiating any immunosuppressant agents to prevent drug effect, and the patients were divided according to disease activity. Cumulative steroid dose was also calculated. As such, the results remain reliable after some adjustments. Instead of using <italic>Salmonella</italic> to stimulate PMNs function, we used <italic>Salmonella</italic>-specific LPS for testing, which may contribute to some confounding. Finally, the study involved rather a small group of SLE patients, particularly when looking at the active versus inactive and immunosuppressant medication sub-groups.</p>
</sec>
<sec id="sec11-0961203312474704" sec-type="conclusions"><title>Conclusions</title>
<p>Immunosuppressant agents cause patients with SLE to be more susceptible to infections but do not influence phagocytic function. Impaired phagocytosis against <italic>Salmonella</italic> is prominent in pediatric-onset SLE subjects, which may result in the high prevalence of <italic>Salmonella</italic> infection. There is no deficiency of peroxidase production and chemotaxis activity among SLE subjects.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>An informed consent was obtained from both the children and their parents before enrollment and the hospital ethics committee approved the study. The final manuscript has been read and approved by all the authors, and each has given the attention necessary to ensure the integrity of the work. The authors would like to thank Huang et al. for the collection and processing of specimens along with their technical assistance for the financial support for this project (number: NSC 98-2314-B-182-002-MY3).</p></ack>
<sec id="sec12-0961203312474704"><title>Funding</title>
<p>This study was supported by Chang Gung Medical Research Progress Grant and National Science Council Grant (NSC-98-2314-B-182A-092-MY3 (IRB 97-2290B)), (NMRPD180611-3(NMRPG386363), (CMRPG400041).</p>
</sec>
<sec id="sec13-0961203312474704"><title>Conflict of interest</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312474704"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>H</given-names></name><name><surname>Reinhard</surname><given-names>E</given-names></name><name><surname>Otmar</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Impaired phagocytosis of apoptotic cell material by monocyte-derived by macrophages from patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1998</year>; <volume>41</volume>: <fpage>1241</fpage>–<lpage>1250</lpage>.</citation></ref>
<ref id="bibr2-0961203312474704"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>PR</given-names></name><name><surname>Carugati</surname><given-names>A</given-names></name><name><surname>Fadok</surname><given-names>VA</given-names></name><etal/></person-group>. <article-title>A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells <italic>in vivo</italic></article-title>. <source>J Exp Med</source> <year>2000</year>; <volume>192</volume>: <fpage>359</fpage>–<lpage>366</lpage>.</citation></ref>
<ref id="bibr3-0961203312474704"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>A</given-names></name><name><surname>Casciola-Rosen</surname><given-names>L</given-names></name></person-group>. <article-title>Auto-antigens as substrates for apoptotic proteases: Implications for the pathogenesis of systemic autoimmune disease</article-title>. <source>Cell Death Differ</source> <year>1999</year>; <volume>6</volume>: <fpage>6</fpage>–<lpage>12</lpage>.</citation></ref>
<ref id="bibr4-0961203312474704"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>JL</given-names></name><name><surname>Yeh</surname><given-names>KW</given-names></name><name><surname>Yao</surname><given-names>TC</given-names></name><etal/></person-group>. <article-title>Pediatric lupus in Asia</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>1414</fpage>–<lpage>1418</lpage>.</citation></ref>
<ref id="bibr5-0961203312474704"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Ou</surname><given-names>LS</given-names></name><etal/></person-group>. <article-title>Risk factors of mortality for salmonella infection in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2002</year>; <volume>29</volume>: <fpage>1214</fpage>–<lpage>1218</lpage>.</citation></ref>
<ref id="bibr6-0961203312474704"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>KC</given-names></name><name><surname>Yao</surname><given-names>TC</given-names></name><name><surname>Yeh</surname><given-names>KW</given-names></name><name><surname>Huang</surname><given-names>JL</given-names></name></person-group>. <article-title>Osteomyelitis in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2004</year>; <volume>31</volume>: <fpage>1340</fpage>–<lpage>1343</lpage>.</citation></ref>
<ref id="bibr7-0961203312474704"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>JL</given-names></name><name><surname>Lin</surname><given-names>GJ</given-names></name><name><surname>Hung</surname><given-names>IJ</given-names></name></person-group>. <article-title>Morbidity and mortality associated with childhood systemic lupus erythematosus</article-title>. <source>Chang Gung Med J</source> <year>1994</year>; <volume>17</volume>: <fpage>113</fpage>–<lpage>120</lpage>.</citation></ref>
<ref id="bibr8-0961203312474704"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MJ</given-names></name><name><surname>Tseng</surname><given-names>HM</given-names></name><name><surname>Huang</surname><given-names>YL</given-names></name><etal/></person-group>. <article-title>Long-term outcome and short-term survival of patients with systemic lupus erythematosus after bacteremia episodes: 6-yr follow-up</article-title>. <source>Rheumatology</source> <year>2008</year>; <volume>47</volume>: <fpage>1352</fpage>–<lpage>1357</lpage>.</citation></ref>
<ref id="bibr9-0961203312474704"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>JJ</given-names></name><name><surname>Ou</surname><given-names>LS</given-names></name><name><surname>Lee</surname><given-names>WI</given-names></name><name><surname>Huang</surname><given-names>JL</given-names></name></person-group>. <article-title>Central nervous system infections in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2005</year>; <volume>32</volume>: <fpage>40</fpage>–<lpage>43</lpage>.</citation></ref>
<ref id="bibr10-0961203312474704"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>JL</given-names></name><name><surname>Hung</surname><given-names>JJ</given-names></name><name><surname>Wu</surname><given-names>KC</given-names></name><etal/></person-group>. <article-title>Septic arthritis in patients with systemic lupus erythematosus: Salmonella and non-salmonella infections compared</article-title>. <source>Semin Arthritis Rheum</source> <year>2006</year>; <volume>36</volume>: <fpage>61</fpage>–<lpage>67</lpage>.</citation></ref>
<ref id="bibr11-0961203312474704"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lekstrom-Himes</surname><given-names>JA</given-names></name><name><surname>Gallin</surname><given-names>JI</given-names></name></person-group>. <article-title>Immunodeficiency diseases caused by defects in phagocytes</article-title>. <source>N Engl J Med</source> <year>2000</year>; <volume>343</volume>: <fpage>1703</fpage>–<lpage>1703</lpage>.</citation></ref>
<ref id="bibr12-0961203312474704"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>AS</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>The 1982 revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>1271</fpage>–<lpage>1277</lpage>.</citation></ref>
<ref id="bibr13-0961203312474704"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>Derivation of the SLEDAI: A disease activity index for lupus patients</article-title>. <source>The Committee on Prognosis Studies in SLE. Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>630</fpage>–<lpage>640</lpage>.</citation></ref>
<ref id="bibr14-0961203312474704"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>HR</given-names></name><name><surname>Chang</surname><given-names>JC</given-names></name><name><surname>Chen</surname><given-names>RF</given-names></name><etal/></person-group>. <article-title>Different antigens trigger different Th1/Th2 reactions in neonatal mononuclear cells (MNCs) relating to T-bet/GATA-3 expression</article-title>. <source>J Leukoc Biol</source> <year>2003</year>; <volume>74</volume>: <fpage>952</fpage>–<lpage>958</lpage>.</citation></ref>
<ref id="bibr15-0961203312474704"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drevets</surname><given-names>DA</given-names></name><name><surname>Campbell</surname><given-names>PA</given-names></name></person-group>. <article-title>Macrophage phagocytosis: Use of fluorescence microscopy to distinguish between extracellular and intracellular bacteria</article-title>. <source>J Immunol Methods</source> <year>1991</year>; <volume>142</volume>: <fpage>31</fpage>–<lpage>38</lpage>.</citation></ref>
<ref id="bibr16-0961203312474704"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szejda</surname><given-names>P</given-names></name><name><surname>Parce</surname><given-names>JW</given-names></name><name><surname>Seeds</surname><given-names>MS</given-names></name><name><surname>Bass</surname><given-names>DA</given-names></name></person-group>. <article-title>Flow cytometric quantitation of oxidative product formation by polymorphonuclear leukocytes during phagocytosis</article-title>. <source>J Immunol</source> <year>1984</year>; <volume>133</volume>: <fpage>3303</fpage>–<lpage>3307</lpage>.</citation></ref>
<ref id="bibr17-0961203312474704"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oben</surname><given-names>JA</given-names></name><name><surname>Foreman</surname><given-names>JC</given-names></name></person-group>. <article-title>A simple quantitative fluorimetric assay of in vitro phagocytosis in human neutrophils</article-title>. <source>J Immunol Methods</source> <year>1988</year>; <volume>112</volume>: <fpage>99</fpage>–<lpage>103</lpage>.</citation></ref>
<ref id="bibr18-0961203312474704"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White-Owen</surname><given-names>C</given-names></name><name><surname>Alexander</surname><given-names>JW</given-names></name><name><surname>Sramkoski</surname><given-names>RM</given-names></name><name><surname>Babcock</surname><given-names>GF</given-names></name></person-group>. <article-title>Rapid whole-blood micro-assay using flow cytometry for measuring neutrophil phagocytosis</article-title>. <source>J Clin Microbiol</source> <year>1992</year>; <volume>30</volume>: <fpage>2071</fpage>–<lpage>2076</lpage>.</citation></ref>
<ref id="bibr19-0961203312474704"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>SS</given-names></name><name><surname>Weinrauch</surname><given-names>Y</given-names></name><name><surname>Munford</surname><given-names>RS</given-names></name><name><surname>Elsbach</surname><given-names>P</given-names></name><name><surname>Weiss</surname><given-names>J</given-names></name></person-group>. <article-title>Deacylation of lipopolysaccharide in whole <italic>Escherichia coli</italic> during destruction by cellular and extracellular components of a rabbit peritoneal inflammatory exudate</article-title>. <source>J Biol Chem</source> <year>1999</year>; <volume>274</volume>: <fpage>36579</fpage>–<lpage>36584</lpage>.</citation></ref>
<ref id="bibr20-0961203312474704"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenzweig</surname><given-names>SD</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name></person-group>. <article-title>Phagocyte immuno-deficiencies and their infections</article-title>. <source>J Allergy Clin Immunol</source> <year>2004</year>; <volume>113</volume>: <fpage>620</fpage>–<lpage>626</lpage>.</citation></ref>
<ref id="bibr21-0961203312474704"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Janko</surname><given-names>C</given-names></name><name><surname>Schorn</surname><given-names>C</given-names></name><name><surname>Grossmayer</surname><given-names>GE</given-names></name><name><surname>Munoz</surname><given-names>LE</given-names></name></person-group>. <article-title>Inflammatory clearance of apoptotic remnants in systemic lupus erythematosus (SLE)</article-title>. <source>Autoimmun Rev</source> <year>2008</year>; <volume>8</volume>: <fpage>9</fpage>–<lpage>12</lpage>.</citation></ref>
<ref id="bibr22-0961203312474704"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>M</given-names></name></person-group>. <article-title>Phagocyte function and cell-mediated immunity in systemic lupus erythematosus</article-title>. <source>Arch Dermatol</source> <year>1977</year>; <volume>113</volume>: <fpage>147</fpage>–<lpage>154</lpage>.</citation></ref>
<ref id="bibr23-0961203312474704"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iliopoulos</surname><given-names>AG</given-names></name><name><surname>Tsokos</surname><given-names>GC</given-names></name></person-group>. <article-title>Immuno-pathogenesis and spectrum of infections in systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source> <year>1996</year>; <volume>25</volume>: <fpage>318</fpage>–<lpage>336</lpage>.</citation></ref>
<ref id="bibr24-0961203312474704"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yi Ren, Tang</surname><given-names>JL</given-names></name><name><surname>Mok</surname><given-names>MY</given-names></name><etal/></person-group>. <article-title>Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2003</year>; <volume>10</volume>: <fpage>2888</fpage>–<lpage>2897</lpage>.</citation></ref>
<ref id="bibr25-0961203312474704"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>SC</given-names></name><name><surname>Tsai</surname><given-names>CY</given-names></name><name><surname>Sun</surname><given-names>KH</given-names></name><etal/></person-group>. <article-title>Decreased spontaneous and lipopolysaccharide stimulated production of interleukin 8 by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus</article-title>. <source>Clin Exp Rheumatol</source> <year>1994</year>; <volume>12</volume>: <fpage>627</fpage>–<lpage>633</lpage>.</citation></ref>
<ref id="bibr26-0961203312474704"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Svenssou</surname><given-names>BO</given-names></name></person-group>. <article-title>Serum factors causing impaired macrophage function in systemic erythematosus</article-title>. <source>Scand J lmmunol</source> <year>1975</year>; <volume>4</volume>: <fpage>145</fpage>–<lpage>150</lpage>.</citation></ref>
<ref id="bibr27-0961203312474704"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vazquez Doval</surname><given-names>J</given-names></name><name><surname>Sanchez Tbarrola</surname><given-names>A</given-names></name></person-group>. <article-title>Defective mononuclear phagocyte function in systemic lupus erythematosus: relationship of FcRII (CD32) with intermediate cytoskeletal filaments</article-title>. <source>J lnvestig Allergol Clin Immunol</source> <year>1993</year>; <volume>3</volume>: <fpage>86</fpage>–<lpage>91</lpage>.</citation></ref>
<ref id="bibr28-0961203312474704"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Passero</surname><given-names>FC</given-names></name><name><surname>Myers</surname><given-names>AR</given-names></name></person-group>. <article-title>Decreased numbers of monocytes in inflammatory exudates in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1981</year>; <volume>8</volume>: <fpage>62</fpage>–<lpage>68</lpage>.</citation></ref>
<ref id="bibr29-0961203312474704"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>O</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Miyachi</surname><given-names>Y</given-names></name></person-group>. <article-title>Herpes zoster in Japanese patients with systemic lupus erythematosus</article-title>. <source>Clin Exp Dermatol</source> <year>1999</year>; <volume>24</volume>: <fpage>327</fpage>–<lpage>328</lpage>.</citation></ref>
<ref id="bibr30-0961203312474704"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahl</surname><given-names>LE</given-names></name></person-group>. <article-title>Herpes zoster infections in systemic lupus erythematosus: Risk factors and outcome</article-title>. <source>J Rheumatol</source> <year>1994</year>; <volume>21</volume>: <fpage>84</fpage>–<lpage>86</lpage>.</citation></ref>
<ref id="bibr31-0961203312474704"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name></person-group>. <article-title>Infectious complications in SLE after immuno-suppressive therapies</article-title>. <source>Curr Opin Rheumatol</source> <year>2003</year>; <volume>15</volume>: <fpage>528</fpage>–<lpage>534</lpage>.</citation></ref>
<ref id="bibr32-0961203312474704"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pablos</surname><given-names>JL</given-names></name><name><surname>Aragon</surname><given-names>A</given-names></name><name><surname>Gomez-Reino</surname><given-names>JJ</given-names></name></person-group>. <article-title>Salmonellosis and systemic lupus erythematosus</article-title>. <source>Report of ten cases. Br J Rheumatol</source> <year>1994</year>; <volume>33</volume>: <fpage>129</fpage>–<lpage>132</lpage>.</citation></ref>
<ref id="bibr33-0961203312474704"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Luis</surname><given-names>A</given-names></name><name><surname>Pigrau</surname><given-names>C</given-names></name><name><surname>Pahissa</surname><given-names>A</given-names></name><name><surname>Fernandez</surname><given-names>F</given-names></name><name><surname>Martinez-Vazquez</surname><given-names>JM</given-names></name></person-group>. <article-title>Infections in 96 cases of systemic lupus erythematosus</article-title>. <source>Med Clin</source> <year>1990</year>; <volume>94</volume>: <fpage>607</fpage>–<lpage>610</lpage>.</citation></ref>
<ref id="bibr34-0961203312474704"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>E</given-names></name><name><surname>Koh</surname><given-names>WH</given-names></name><name><surname>Loh</surname><given-names>SF</given-names></name><etal/></person-group>. <article-title>Non-thyphoidal salmonellosis in patients with systemic lupus erythematosus</article-title>. <source>A study of fifty patients and a review of the literature. Lupus</source> <year>2001</year>; <volume>10</volume>: <fpage>87</fpage>–<lpage>92</lpage>.</citation></ref>
<ref id="bibr35-0961203312474704"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>S</given-names></name><name><surname>Kramer</surname><given-names>SB</given-names></name><name><surname>Radin</surname><given-names>A</given-names></name><name><surname>Holzman</surname><given-names>R</given-names></name></person-group>. <article-title>Salmonella bacteremia in systemic lupus erythematosus</article-title>. <source>Eight-year experience at a municipal hospital. Arthritis Rheum</source> <year>1985</year>; <volume>28</volume>: <fpage>75</fpage>–<lpage>79</lpage>.</citation></ref>
<ref id="bibr36-0961203312474704"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noël</surname><given-names>V</given-names></name><name><surname>Lortholary</surname><given-names>O</given-names></name><name><surname>Casassus</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <year>2001</year>; <volume>60</volume>: <fpage>1141</fpage>–<lpage>1144</lpage>.</citation></ref>
<ref id="bibr37-0961203312474704"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Insoo</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name></person-group>. <article-title>Infectious complications in SLE after immuno-suppressive therapies</article-title>. <source>Current Opinion in Rheumatol</source> <year>2003</year>; <volume>15</volume>: <fpage>528</fpage>–<lpage>534</lpage>.</citation></ref>
<ref id="bibr38-0961203312474704"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manzi</surname><given-names>S</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Kutzer</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Herpes zoster in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1995</year>; <volume>22</volume>: <fpage>1254</fpage>–<lpage>1258</lpage>.</citation></ref>
<ref id="bibr39-0961203312474704"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illei</surname><given-names>GG</given-names></name><name><surname>Austin</surname><given-names>HA</given-names></name><name><surname>Crane</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis</article-title>. <source>Ann Intern Med</source> <year>2001</year>; <volume>135</volume>: <fpage>248</fpage>–<lpage>257</lpage>.</citation></ref>
<ref id="bibr40-0961203312474704"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ginzler</surname><given-names>E</given-names></name><name><surname>Diamond</surname><given-names>H</given-names></name><name><surname>Kaplan</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1978</year>; <volume>21</volume>: <fpage>37</fpage>–<lpage>44</lpage>.</citation></ref>
</ref-list>
<app-group>
<app id="app1-0961203312474704"><title/>
<sec id="sec14-0961203312474704"><title/>
<p>
<table-wrap id="table4-0961203312474704" position="float"><label>Appendix 1</label><caption><p>PMNs function in SLE with and without history of infection</p></caption>
<graphic alternate-form-of="table4-0961203312474704" xlink:href="10.1177_0961203312474704-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>H<sub>2</sub>O<sub>2</sub> in SLE with and without history of infection</th>
<th>Number</th>
<th>Mean ± SD (%)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>SLE without history of infection</td>
<td>22</td>
<td>98.81 ± 0.45</td>
</tr>
<tr>
<td>SLE with history of infection</td>
<td>12</td>
<td>98.71 ± 0.39</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>98.71 ± 0.33</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. SLE without history of infection</td>
<td/>
<td>0.99</td>
</tr>
<tr>
<td>NC vs. SLE with history of infection</td>
<td/>
<td>0.98</td>
</tr>
<tr>
<td>SLE without history of infection vs. SLE with history of infection</td>
<td/>
<td>1.00</td>
</tr>
<tr>
<td><bold>Chemotaxis in SLE with and without history of infection</bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>SLE without history of infection</td>
<td>22</td>
<td>52.1 ± 23.56</td>
</tr>
<tr>
<td>SLE with history of infection</td>
<td>12</td>
<td>58.92 ± 32.57</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>63.2 ± 12.90</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. SLE without history of infection</td>
<td/>
<td>0.24</td>
</tr>
<tr>
<td>NC vs. SLE with history of infection</td>
<td/>
<td>0.86</td>
</tr>
<tr>
<td>SLE without history of infection vs. SLE with history of infection</td>
<td/>
<td>0.70</td>
</tr>
<tr>
<td colspan="3"><bold>Phagocytosis in SLE with and without history of infection</bold></td>
</tr>
<tr>
<td><bold><italic>E. coli</italic></bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>SLE without history of infection</td>
<td>22</td>
<td>87.92 ± 7.17</td>
</tr>
<tr>
<td>SLE with history of infection</td>
<td>12</td>
<td>87.93 ± 6.63</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>88.25 ± 5.03</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. SLE without history of infection</td>
<td/>
<td>0.98</td>
</tr>
<tr>
<td>NC vs. SLE with history of infection</td>
<td/>
<td>0.99</td>
</tr>
<tr>
<td>SLE without history of infection vs. SLE with history of infection</td>
<td/>
<td>1.00</td>
</tr>
<tr>
<td><bold><italic>S. aureus</italic></bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>SLE without history of infection</td>
<td>22</td>
<td>87.12 ± 7.39</td>
</tr>
<tr>
<td>SLE with history of infection</td>
<td>12</td>
<td>88.28 ± 3.90</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>91.52 ± 5.06</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. SLE without history of infection</td>
<td/>
<td>0.05</td>
</tr>
<tr>
<td>NC vs. SLE with history of infection</td>
<td/>
<td>0.30</td>
</tr>
<tr>
<td>SLE without history of infection vs. SLE with history of infection</td>
<td/>
<td>0.86</td>
</tr>
<tr>
<td><bold>LPS (<italic>Salmonella</italic>)</bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>SLE without history of infection</td>
<td>22</td>
<td>73.28 ± 21.07</td>
</tr>
<tr>
<td>SLE with history of infection</td>
<td>12</td>
<td>76.87 ± 21.17</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>94.32 ± 2.88</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. SLE without history of infection</td>
<td/>
<td>&lt;0.01<xref ref-type="table-fn" rid="table-fn2-0961203312474704">*</xref></td>
</tr>
<tr>
<td>NC vs. SLE with history of infection</td>
<td/>
<td>0.01<xref ref-type="table-fn" rid="table-fn2-0961203312474704">*</xref></td>
</tr>
<tr>
<td>SLE without history of infection vs. SLE with history of infection</td>
<td/>
<td>0.83</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312474704"><p>Phagocytosis against LPS (<italic>Salmonella</italic>) antigen was lower in SLE patients with and without history of severe infection compared to NC (<italic>p </italic>≤ 0.01). NC: normal control; SLE: systemic lupus erythematosus; SD: standard deviation.</p></fn>
<fn id="table-fn2-0961203312474704"><label>*</label><p><italic>p </italic>≤ 0.01</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0961203312474704" position="float"><label>Appendix 2</label><caption><p>PMNs function in active and inactive SLE</p></caption>
<graphic alternate-form-of="table5-0961203312474704" xlink:href="10.1177_0961203312474704-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>H<sub>2</sub>O<sub>2</sub> active and inactive stage</th>
<th>Number</th>
<th>Mean ± SD (%)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Inactive SLE</td>
<td>9</td>
<td>97.86 ± 2.50</td>
</tr>
<tr>
<td>Active SLE</td>
<td>25</td>
<td>99.13 ± 0.92</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>98.87 ± 1.25</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. inactive SLE</td>
<td/>
<td>0.14</td>
</tr>
<tr>
<td>NC vs. active SLE</td>
<td/>
<td>0.30</td>
</tr>
<tr>
<td>Inactive SLE vs. active SLE</td>
<td/>
<td>0.86</td>
</tr>
<tr>
<td><bold>Chemotaxis active and inactive stage</bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>Inactive SLE</td>
<td>9</td>
<td>60.22 ± 12.14</td>
</tr>
<tr>
<td>Active SLE</td>
<td>25</td>
<td>52.28 ± 29.98</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>63.20 ± 12.90</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. inactive SLE</td>
<td/>
<td>0.94</td>
</tr>
<tr>
<td>NC vs. active SLE</td>
<td/>
<td>0.22</td>
</tr>
<tr>
<td>Inactive SLE vs. active SLE</td>
<td/>
<td>0.65</td>
</tr>
<tr>
<td><bold>Phagocytosis active and inactive stage</bold></td>
<td/>
<td/>
</tr>
<tr>
<td><bold><italic>E. coli</italic></bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>Inactive SLE</td>
<td>9</td>
<td>84.93 ± 7.78</td>
</tr>
<tr>
<td>Active SLE</td>
<td>25</td>
<td>88.88 ± 6.43</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>88.25 ± 5,03</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. inactive SLE</td>
<td/>
<td>0.41</td>
</tr>
<tr>
<td>NC vs. active SLE</td>
<td/>
<td>0.94</td>
</tr>
<tr>
<td>Inactive SLE vs. active SLE</td>
<td/>
<td>0.29</td>
</tr>
<tr>
<td><bold><italic>S. aureus</italic></bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>Inactive SLE</td>
<td>9</td>
<td>86.44 ± 4.84</td>
</tr>
<tr>
<td>Active SLE</td>
<td>25</td>
<td>87.9 ± 6.75</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>91.52 ± 5.06</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. inactive SLE</td>
<td/>
<td>0.11</td>
</tr>
<tr>
<td>NC vs. active SLE</td>
<td/>
<td>0.10</td>
</tr>
<tr>
<td>Inactive SLE vs. active SLE</td>
<td/>
<td>0.83</td>
</tr>
<tr>
<td><bold>LPS (<italic>Salmonella</italic>)</bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>Inactive SLE</td>
<td>9</td>
<td>73.57 ± 22.66</td>
</tr>
<tr>
<td>Active SLE</td>
<td>25</td>
<td>74.91 ± 20.71</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>94.32 ± 2.88</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. inactive SLE</td>
<td/>
<td>&lt;0.01<xref ref-type="table-fn" rid="table-fn4-0961203312474704">*</xref></td>
</tr>
<tr>
<td>NC vs. active SLE</td>
<td/>
<td>&lt;0.01<xref ref-type="table-fn" rid="table-fn4-0961203312474704">*</xref></td>
</tr>
<tr>
<td>Inactive SLE vs. active SLE</td>
<td/>
<td>0.98</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203312474704"><p>Phagocytosis against LPS (<italic>Salmonella</italic>) antigen was lower in SLE patients regardless of active or inactive disease stage compared to NC (<italic>p </italic>≤ 0.01). NC: normal control; SLE: systemic lupus erythematosus; SLEDAI &gt;4 points, Active SLE; SD: standard deviation.</p></fn>
<fn id="table-fn4-0961203312474704"><label>*</label><p><italic>p </italic>≤ 0.01.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table6-0961203312474704" position="float"><label>Appendix 3</label><caption><p>PMNs function in SLE with and without immunosuppressant medication</p></caption>
<graphic alternate-form-of="table6-0961203312474704" xlink:href="10.1177_0961203312474704-table6.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>H<sub>2</sub>O<sub>2</sub> in SLE with/without immunosuppressant medication</th>
<th>Number</th>
<th>Mean ± SD (%)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>SLE without immunosuppressant medication</td>
<td>10</td>
<td>99.57 ± 0.25</td>
</tr>
<tr>
<td>SLE with immunosuppressant medication</td>
<td>24</td>
<td>98.68 ± 1.75</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>98.71 ± 1.38</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. SLE without immunosuppressant medication</td>
<td/>
<td>0.65</td>
</tr>
<tr>
<td>NC vs. SLE with immunosuppressant medication</td>
<td/>
<td>0.68</td>
</tr>
<tr>
<td>SLE without immunosuppressant medication vs. SLE with immunosuppressant medication</td>
<td/>
<td>1.00</td>
</tr>
<tr>
<td><bold>Chemotaxis in SLE with/without immunosuppressant medication</bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>SLE without immunosuppressant medication</td>
<td>10</td>
<td>56.40 ± 44.26</td>
</tr>
<tr>
<td>SLE with immunosuppressant medication</td>
<td>24</td>
<td>53.78 ± 15.72</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>63.2 ± 12.90</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. SLE without immunosuppressant medication</td>
<td/>
<td>0.72</td>
</tr>
<tr>
<td>NC vs. SLE with immunosuppressant medication</td>
<td/>
<td>0.35</td>
</tr>
<tr>
<td>SLE without immunosuppressant medication vs. SLE with immunosuppressant medication</td>
<td/>
<td>0.95</td>
</tr>
<tr>
<td><bold>Phagocytosis in SLE with/without immunosuppressant medication</bold></td>
<td/>
<td/>
</tr>
<tr>
<td><bold><italic>E. coli</italic></bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>SLE without immunosuppressant medication</td>
<td>10</td>
<td>90.74 ± 8.72</td>
</tr>
<tr>
<td>SLE with immunosuppressant medication</td>
<td>24</td>
<td>86.70 ± 5.70</td>
</tr>
<tr>
<td>NC</td>
<td>25</td>
<td>88.25 ± 5.03</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. SLE without immunosuppressant medication</td>
<td/>
<td>0.56</td>
</tr>
<tr>
<td>NC vs. SLE with immunosuppressant medication</td>
<td/>
<td>0.68</td>
</tr>
<tr>
<td>SLE without immunosuppressant medication vs. SLE with immunosuppressant medication</td>
<td/>
<td>0.22</td>
</tr>
<tr>
<td><bold><italic>S. aureus</italic></bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>SLE without immunosuppressant medication</td>
<td>10</td>
<td>87.92 ± 9.65</td>
</tr>
<tr>
<td>SLE with immunosuppressant medication</td>
<td>24</td>
<td>87.38 ± 4.41</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>91.52 ± 5.06</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. SLE without immunosuppressant medication</td>
<td/>
<td>0.27</td>
</tr>
<tr>
<td>NC vs. SLE with immunosuppressant medication</td>
<td/>
<td>0.06</td>
</tr>
<tr>
<td>SLE without immunosuppressant medication vs. SLE with immunosuppressant medication</td>
<td/>
<td>0.97</td>
</tr>
<tr>
<td><bold>LPS (<italic>Salmonella</italic>)</bold></td>
<td><bold>Number</bold></td>
<td><bold>%</bold></td>
</tr>
<tr>
<td>SLE without immunosuppressant medication</td>
<td>10</td>
<td>71.55 ± 18.90</td>
</tr>
<tr>
<td>SLE with immunosuppressant medication</td>
<td>24</td>
<td>75.91 ± 21.90</td>
</tr>
<tr>
<td>Normal control</td>
<td>25</td>
<td>94.32 ± 2.88</td>
</tr>
<tr>
<td><bold>Comparison</bold></td>
<td/>
<td><bold><italic>p</italic>-value</bold></td>
</tr>
<tr>
<td>NC vs. SLE without immunosuppressant medication</td>
<td/>
<td>&lt;0.01<xref ref-type="table-fn" rid="table-fn9-0961203312474704">*</xref></td>
</tr>
<tr>
<td>NC vs. SLE with immunosuppressant medication</td>
<td/>
<td>&lt;0.01<xref ref-type="table-fn" rid="table-fn9-0961203312474704">*</xref></td>
</tr>
<tr>
<td>SLE without immunosuppressant medication vs. SLE with immunosuppressant medication</td>
<td/>
<td>0.78</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0961203312474704"><label>*</label><p><italic>p </italic>≤ 0.01</p></fn>
<fn id="table-fn10-0961203312474704"><p>Phagocytosis against LPS (<italic>Salmonella</italic>) antigen was lower in SLE patients using immunosuppressant agents compared to NC (p<italic> </italic>≤ 0.01). NC: normal control; SLE: systemic lupus erythematosus; SD: standard deviation.</p></fn></table-wrap-foot>
</table-wrap>
</p>
</sec>
</app>
</app-group>
</back>
</article>